Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival.

Autor: Gómez HL; Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú. hgomez@inen.sld.pe, Samanéz C, Campana F, Neciosup SP, Vera L, Casanova L, Leon J, Flores C, de Mendoza FH, Casteñeda CA, Pinto JA, Vallejos CS

Publikováno v: Hematology/oncology and stem cell therapy [Hematol Oncol Stem Cell Ther] 2012; Vol. 5 (3), pp. 152-7.